CD177 and renal cell carcinoma: We further confirmed the suppressive capacity of CD177+ TI Treg cells from another independent experiment with CD177+ and CD177− TI Treg cells from 7 renal cell carcinoma (RCC) specimens when Teff cells were activated by monocyte derived dendritic cells (as antigen presenting cells, APC) at 5:1 ratio (Teff/Treg) (Fig. 7c).